Rampant IPO speculation - is the pace accelerating?
In the first quarter of 2025, Stada, a notable player in the biosimilars market, experienced significant growth and record highs. The German pharmaceutical company's Ustekinumab biosimilar, a reference drug being Stelara by Johnson & Johnson, has contributed to this success in the biosimilars segment.
The segment for specialty pharmaceuticals, including biosimilars, performed exceptionally well, showing a 22% increase in the first quarter of 2025. This surge propelled Stada to a revenue of 1.08 billion euros, marking a 4% growth compared to the previous year. The company's EBITDA also reached a record high of 245 million euros.
Stada's product portfolio extends beyond generic drugs. In addition to its biosimilars, the company offers a diverse range of products, including sun protection products under the Ladival brand and cold remedies like Grippostad.
Rumors of an Initial Public Offering (IPO) have been circulating since 2022, with potential plans for the IPO as early as October 2022. However, the exact timeline for Stada's stock exchange comeback remains dependent on market conditions. The IPO preparation targets a valuation around 10 billion euros and is scheduled for autumn 2025.
The shareholders ahead of the planned IPO include primarily the current private investors. Specific major shareholders are not explicitly detailed in the available sources.
DER AKTIONÄR will continue to monitor the situation regarding Stada's potential IPO. Any further potential IPO news related to Stada will be reported by DER AKTIONÄR, providing updates as they become available.
The potential IPO follows reports of stalled talks for a sale to London-based financial investor CapVest Partners. Bain Capital and Cinven, the current owners of Stada, acquired the company for billions of euros in 2017 and delisted it from the stock exchange.
Stada's success in the first quarter of 2025 underscores the company's resilience and growth potential, making it an exciting prospect for investors. As the IPO approaches, the pharmaceutical industry will be watching closely to see how Stada navigates this new phase in its journey.
Read also:
- Developing a Sales Strategy: Methods, Sample Plans, and Templates for Sales Plans
- Events that transpired on the night of August 13, 2025.
- Manchester-based entrepreneur Amman Ahmed propelled an unusual venture to an 8-digit empire, without external financing. This is the story of how he crafted a groundbreaking genre in the world of animal-oriented media, one growl and rhythm at a time.
- Cooking Quantity of Beef Corresponds to Citizens' Salaries - Analysts Disclose
